Drug Profile
C5a receptor antagonists - G2 Therapies/Novo Nordisk
Alternative Names: NeutrazumabLatest Information Update: 19 Jan 2011
Price :
$50
*
At a glance
- Originator G2 Therapies
- Developer G2 Therapies; Novo Nordisk
- Class Monoclonal antibodies
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Aug 2005 This programme is available for licensing (http://www.g2therapies.com.au)
- 23 Aug 2005 Preclinical trials in Rheumatoid arthritis in Australia (unspecified route)